企业动态_辛伯至生物科技(浙江)有限责任公司,辛伯至

Exhibition Review | Sinboda Technology Makes a Brilliant Appearance at the 2026 Sanya International Seed Scientist Congress

As an innovative enterprise in the AI × Engineering field, Sinboda Technology was invited to exhibit at the 2026 Sanya International Seed Scientist Congress and International Seed Science and Technology Expo. Leveraging its leading AI-driven single-cell manipulation technology, it garnered widespread attention, and received on-site guidance from multiple academicians at its booth, along with in-depth media coverage.

Exhibition Review | Sinboda Shines at the 10th AFLAS Congress

October 21-23, 2025 – The 10th Congress of the Asian Federation of Laboratory Animal Science Associations (AFLAS) and the 18th Chinese Annual Meeting of Laboratory Animal Science and Technology were successfully held in Hangzhou, Sinboda was honored to be invited to this Congress.

AI Empowers New Developments in the Livestock Industry, Exploring New Pathways for Industrial Upgrading | Sinboda Special Seminar Successfully Held

On September 13, 2025, a professional seminar themed "AI Empowering New Developments in the Livestock Industry" was successfully held at Sinboda Technology (Zhejiang) Co., Ltd.

【Strategic Partnership】Sinboda and China National Pharmaceutical Machinery (Shanghai) Corporation Sign First Purchase Order of RMB 21 Million

On August 6, 2025, Sinboda Technology and China National Pharmaceutical Machinery (Shanghai) Corporation reached an agreement on procurement cooperation and signed a purchase order of RMB 21 million.

Sinboda reshapes micro-manipulation and detection through innovation in life science technology platforms, leading a new paradigm of AI-powered healthcare.

In less than one year, Sinboda has achieved a full-process breakthrough from technological R&D to market implementation, completed the construction of three core technology platforms, and launched two life science instruments with world-class innovation: the Single-Cell Micro-Nano Manipulation System ScimaX and the Single-Molecule Conformation Immunoassay System SimdaX. Clinically, these are respectively used for non-invasive prenatal diagnosis using fetal nucleated red blood cells and early blood-based detection of Alzheimer's and Parkinson's diseases, marking the first step in reshaping the industry landscape.